Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose pharmacokinetics of doxorubicin during TACE with DC Bead in hepatocellular carcinoma
2013-001244-56Phase 4Completed
- Sponsor
- Department of Pharmacy, Uppsala University
- Start
- May 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of doxorubicin in hepatocellular carcinoma (HCC), sponsored by Department of Pharmacy, Uppsala University. Primary endpoint: Primary pharmacokinetic parameters of doxorubicin and active metabolite. Started May 2013; status: completed.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2013-001244-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001244-56.